Stock A068270 CELLTRION, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Celltrion, Inc.

Equities

A068270

KR7068270008

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
176,200 KRW -0.62% Intraday chart for Celltrion, Inc. -2.06% -12.56%
May. 24 Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe CI
May. 10 Celltrion's Q1 Attributable Profit Slumps 86% MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe
Celltrion - Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally
Celltrion USA announces two-year data for ZYMFENTRA(infliximab-dyyb) to be presented at Digestive Disease Week (DDW) 2024 Conference
Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Orders
Celltrion's Q1 Attributable Profit Slumps 86%
Market Share of Celltrion’s Remsima Rises to 74% in Europe
MDL Panel Grants Transfer Of Aflibercept BPCIA Case
Celltrion, Inc. announces an Equity Buyback for 436,047 shares.
Celltrion, Inc. authorizes a Buyback Plan.
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on March 5, 2024.
Updates On Aflibercept BPCIA Litigation
Celltrion, Inc.'s Equity Buyback announced on March 5, 2024, has closed with 425,895 shares, representing 0.21% for KRW 78,072.21 million.
Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S.
Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
South Korean Shares Close Higher on Tech Gains; Celltrion Shares Add 1% on Zymfentra Launch in the US
Celltrion's Autoimmune Disease Treatment Hits US Markets
South Korean Shares Slightly Slip as Investors Seek Cues on Future Rate Direction from US Fed
Celltrion Announces 75 Billion Won Share Buyback Plan
Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab)
Celltrion, Inc. announces an Equity Buyback for 425,895 shares.
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A068270 Stock
  4. News Celltrion, Inc.
  5. Other languages